PortfoliosLab logoPortfoliosLab logo
ACET vs. CRSP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ACET vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Adicet Bio, Inc. (ACET) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ACET achieves a -7.01% return, which is significantly lower than CRSP's -0.69% return.


ACET

1D
-3.45%
1M
-7.34%
YTD
-7.01%
6M
-8.87%
1Y
-37.18%
3Y*
-54.94%
5Y*
-47.50%
10Y*

CRSP

1D
0.12%
1M
-2.80%
YTD
-0.69%
6M
-6.98%
1Y
36.91%
3Y*
-7.12%
5Y*
-14.40%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ACET vs. CRSP - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
ACET
Adicet Bio, Inc.
-7.01%-45.30%-49.10%-78.86%-48.89%24.48%34.71%-82.71%-48.93%
CRSP
CRISPR Therapeutics AG
-0.69%33.23%-37.12%54.00%-46.36%-50.51%151.39%113.18%-27.58%

Correlation

The correlation between ACET and CRSP is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.31

Correlation (3Y)
Calculated over the trailing 3-year period

0.32

Correlation (5Y)
Calculated over the trailing 5-year period

0.38

Correlation (All Time)
Calculated using the full available price history since Jan 29, 2018

0.32

Fundamentals

Market Cap

ACET:

$84.13M

CRSP:

$5.00B

EPS

ACET:

-$15.00

CRSP:

-$6.24

PB Ratio

ACET:

0.60

CRSP:

2.76

Total Revenue (TTM)

ACET:

$0.00

CRSP:

$4.10M

Gross Profit (TTM)

ACET:

-$1.47M

CRSP:

-$171.17M

EBITDA (TTM)

ACET:

-$110.77M

CRSP:

-$509.21M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACET vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACET
ACET Risk / Return Rank: 2121
Overall Rank
ACET Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
ACET Sortino Ratio Rank: 2222
Sortino Ratio Rank
ACET Omega Ratio Rank: 2323
Omega Ratio Rank
ACET Calmar Ratio Rank: 2020
Calmar Ratio Rank
ACET Martin Ratio Rank: 2323
Martin Ratio Rank

CRSP
CRSP Risk / Return Rank: 5858
Overall Rank
CRSP Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
CRSP Sortino Ratio Rank: 6060
Sortino Ratio Rank
CRSP Omega Ratio Rank: 5656
Omega Ratio Rank
CRSP Calmar Ratio Rank: 5959
Calmar Ratio Rank
CRSP Martin Ratio Rank: 5555
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACET vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Adicet Bio, Inc. (ACET) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ACETCRSPDifference
Sharpe ratioReturn per unit of total volatility

-1.10

Sortino ratioReturn per unit of downside risk

-1.65

Omega ratioGain probability vs. loss probability

0.96

1.15

-0.19

Calmar ratioReturn relative to maximum drawdown

-0.59

0.88

-1.47

Martin ratioReturn relative to average drawdown

-0.92

1.49

-2.40

ACET vs. CRSP - Sharpe Ratio Comparison

The current ACET Sharpe Ratio is -0.50, which is lower than the CRSP Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of ACET and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ACETCRSPDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.50

0.60

-1.10

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.53

-0.24

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.51

0.23

-0.74

Drawdowns

ACET vs. CRSP - Drawdown Comparison

The maximum ACET drawdown since its inception was -99.74%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for ACET and CRSP.


Loading charts...

Drawdown Indicators


ACETCRSPDifference

Max Drawdown

Largest peak-to-trough decline

-99.74%

-85.11%

-14.63%

Max Drawdown (1Y)

Largest decline over 1 year

-63.28%

-42.25%

-21.03%

Max Drawdown (3Y)

Largest decline over 3 years

-93.31%

-64.91%

-28.40%

Max Drawdown (5Y)

Largest decline over 5 years

-98.20%

-80.68%

-17.52%

Current Drawdown

Current decline from peak

-99.66%

-75.20%

-24.46%

Average Drawdown

Average peak-to-trough decline

-85.32%

-49.17%

-36.15%

Ulcer Index

Depth and duration of drawdowns from previous peaks

40.50%

24.92%

+15.58%

Volatility

ACET vs. CRSP - Volatility Comparison

Adicet Bio, Inc. (ACET) has a higher volatility of 20.67% compared to CRISPR Therapeutics AG (CRSP) at 14.90%. This indicates that ACET's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ACETCRSPDifference

Volatility (1M)

Calculated over the trailing 1-month period

20.67%

14.90%

+5.77%

Volatility (6M)

Calculated over the trailing 6-month period

49.61%

42.49%

+7.12%

Volatility (1Y)

Calculated over the trailing 1-year period

74.31%

61.68%

+12.63%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

90.77%

60.46%

+30.31%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

93.79%

64.27%

+29.52%

Dividends

ACET vs. CRSP - Dividend Comparison

Neither ACET nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ACET vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Adicet Bio, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B202220232024202520260
1.46M
(ACET) Total Revenue
(CRSP) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ACET and CRSP have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ACET has higher volatility (20.67%) compared to CRSP (14.90%). In terms of maximum drawdown, ACET dropped -99.74% vs CRSP's -85.11%.

CRSP currently has the higher Sharpe Ratio (0.60 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ACET and CRSP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer